Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 2/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27266319 | 0.83 | SLC6A3 (0.43) | CYP2C19MEN1KMT2APTGS2 | |
| SCHEMBL1363093 | 0.82 | CYP2C19 (0.68) | CYP2C19CPN1CPB2LMNAMAPK1 | |
| SCHEMBL28857969 | 0.82 | CYP2C19 (0.47) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL2795153 | 0.78 | SLC6A3 (0.35) | CYP2C19LMNA | |
| SCHEMBL10897018 | 0.78 | CPN1 (0.44) | CPN1CPB2MEN1KMT2AMDM2 | |
| SCHEMBL31626107 | 0.77 | CTSB (0.41) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL27264689 | 0.77 | CTSB (0.41) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL27264692 | 0.77 | CPN1 (0.43) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL27264382 | 0.75 | CPN1 (0.42) | CYP2C19CPN1CPB2MEN1KMT2A | |
| SCHEMBL2797964 | 0.75 | CYP3A4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2024054845-A1 | MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP2C19 924/4885CPN1 3495/4885CPB2 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.